ENTRY       D12241                      Drug
NAME        Regdanvimab (INN);
            Regkirona (TN)
SEQUENCE    (Heavy chain)
            QITLKESGPT LVKPTQTLTL TCSFSGFSLS TSGVGVGWIR QPPGKALEWL ALIDWDDNKY
            HTTSLKTRLT ISKDTSKNQV VLTMTNMDPV DTATYYCARI PGFLRYRNRY YYYGMDVWGQ
            GTTVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT
            FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC
            PAPELLGGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT
            KPREEQYNST YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY
            TLPPSRDELT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK
            LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK
            (Light chain)
            ELVLTQPPSV SAAPGQKVTI SCSGSSSNIG NNYVSWYQQL PGTAPKLLIY DNNKRPSGIP
            DRFSGSKSGT SATLGITGLQ TGDEADYYCG TWDSSLSAGV FGGGTELTVL GQPKAAPSVT
            LFPPSSEELQ ANKATLVCLI SDFYPGAVTV AWKADGSPVK AGVETTKPSK QSNNKYAASS
            YLSLTPEQWK SHRSYSCQVT HEGSTVEKTV APTECS
            (Disulfide bridge: H22-H97, H155-H211, H231-L215, H237-H'237, H240-H'240, H272-H332, H378-H436, H'22-H'97, H'155-H'211, H'231-L'215, H'272-H'332, H'378-H'436, L22-L89, L138-L197, L'22-L'89, L'138-L'197)
  TYPE      Peptide
CLASS       Antiviral
             DG03174  Anti-SARS-CoV-2 agent
REMARK      ATC code: J06BD06
EFFICACY    Antiviral
  TYPE      Monoclonal antibody
COMMENT     Treatment of adults with coronavirus disease 2019 (COVID-19)
TARGET      SARS-CoV-2 spike glycoprotein [KO:K24152]
  PATHWAY   ko03230(K24152)  Viral genome structure
            ko05171(K24152)  Coronavirus disease - COVID-19
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             J ANTIINFECTIVES FOR SYSTEMIC USE
              J06 IMMUNE SERA AND IMMUNOGLOBULINS
               J06B IMMUNOGLOBULINS
                J06BD Antiviral monoclonal antibodies
                 J06BD06 Regdanvimab
                  D12241  Regdanvimab (INN)
            Drug groups [BR:br08330]
             Antiviral
              DG03174  Anti-SARS-CoV-2 agent
               D12241  Regdanvimab
            Antimicrobials [BR:br08307]
             Antivirals
              Entry, fusion or uncoating inhibitor
               Coronavirus spike protein
                D12241  Regdanvimab (INN)
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D12241
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D12241
DBLINKS     CAS: 2444308-95-4
///
